Taiwan AI drug discovery and digital medicine companies and pipeline landscape (November 2026) | Drugnews
At least 1 Taiwanese biotech company is active in AI drug discovery and digital medicine, with 1 asset in development or on the market. The most advanced is Dasher (7829)’s YA-101 (Phase 2; Multiple System Atrophy). Data as of 2026-11-01; updated as new information becomes available.
Taiwan pipelines
1 / 1
| Dasher (7829) | 7829 | YA-101 | Not disclosed | Phase 2; active not recruiting | Multiple System Atrophy | Not disclosed | 2026-07-29 | 2026-08-19 2026-07-29 |
No matches. Clear the search to show all rows.
Recent events
- announced completed enrollment in the global Phase 2 trial of YA-101. Source
Related Drugnews analysis
FAQ
Which Taiwanese companies are developing AI drug discovery and digital medicine?
Currently, 1 company is included: Dasher (7829). Their drugs, stages and indications are in the pipeline table above.
Which Taiwan-listed stocks are linked to AI drug discovery and digital medicine?
Taiwan Emerging Stock Board companies directly involved in AI drug discovery and digital medicine R&D, manufacturing or licensing include: Dasher (7829). Compiled from public information; this is not investment advice.
Which Taiwanese AI drug discovery and digital medicine program is most advanced?
Dasher (7829)’s YA-101 is at Phase 2 (Multiple System Atrophy).
What is the latest important development in Taiwan’s AI drug discovery and digital medicine sector?
The latest record is 2026-07-29: Dasher (7829) announced completed enrollment in the global Phase 2 trial of YA-101.
SourceHow often is this data updated?
Data as of 2026-11-01; updated when companies announce new developments or clinical progress. Every entry includes its original source and date.